OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lessened its position in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 45.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 209,476 shares of the medical instruments supplier’s stock after selling 174,963 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.29% of OraSure Technologies worth $1,718,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Trexquant Investment LP grew its position in shares of OraSure Technologies by 3.3% during the 3rd quarter. Trexquant Investment LP now owns 64,644 shares of the medical instruments supplier’s stock valued at $383,000 after acquiring an additional 2,049 shares during the period. Diversified Trust Co grew its holdings in OraSure Technologies by 17.7% in the fourth quarter. Diversified Trust Co now owns 16,031 shares of the medical instruments supplier’s stock valued at $131,000 after purchasing an additional 2,406 shares during the period. Deutsche Bank AG increased its position in shares of OraSure Technologies by 3.1% in the third quarter. Deutsche Bank AG now owns 196,468 shares of the medical instruments supplier’s stock valued at $1,165,000 after buying an additional 5,875 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of OraSure Technologies by 1.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 496,796 shares of the medical instruments supplier’s stock worth $2,946,000 after buying an additional 9,400 shares during the period. Finally, Tocqueville Asset Management L.P. purchased a new position in shares of OraSure Technologies during the 3rd quarter valued at approximately $75,000. Hedge funds and other institutional investors own 93.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Evercore ISI cut their price target on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a report on Thursday, April 4th. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat, OraSure Technologies has a consensus rating of “Hold” and an average target price of $6.38.

OraSure Technologies Price Performance

NASDAQ OSUR opened at $5.35 on Tuesday. The stock’s 50 day simple moving average is $6.44 and its 200-day simple moving average is $6.82. The company has a market cap of $409.33 million, a PE ratio of 7.43 and a beta of 0.15. OraSure Technologies, Inc. has a 1-year low of $4.38 and a 1-year high of $8.45.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.09. OraSure Technologies had a return on equity of 14.50% and a net margin of 13.23%. The company had revenue of $75.88 million for the quarter, compared to analyst estimates of $74.13 million. During the same quarter last year, the firm posted $0.21 EPS. The firm’s revenue for the quarter was down 38.3% on a year-over-year basis. On average, equities research analysts anticipate that OraSure Technologies, Inc. will post -0.11 EPS for the current fiscal year.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.